‘ALL’ about metabolism: repurposing drugs for acute lymphoblastic leukaemia
Examining whether a group of drugs called gliflozins could be used to treat T-ALL
Developing innovative new treatments for difficult to treat types of medulloblastoma
Developing and delivering small molecule drug and immunotherapy combinations for MYC-driven medulloblastoma: Efficacy, evolution and exploitation.
Understanding the evolution of neuroblastoma to improve treatment
Single-cell transcriptomics linked to lineage tracing to interrogate the role of intra-tumour heterogeneity in shaping therapeutic susceptibility and resistance in paediatric cancer
Improving treatment decisions and outcomes in low grade glioma
Development of a multi-factorial prognostic model to optimise treatment decision making and outcomes in paediatric low-grade glioma
Using next-generation gene technology to help children with blood cancers in low-income countries.
Defining the molecular landscape of paediatric and adolescent acute leukaemia in Tanzania
Towards chemotherapy-free treatment of lymphoid tumours in children with solid organ transplants
Towards chemotherapy-free treatment of paediatric post-transplant lymphoproliferative disorders
Living with treatment-related hearing loss: Experiences of survivors of childhood brain cancer
Living with treatment-related hearing loss: Experiences of survivors of childhood brain cancer
High-specificity killing of brain tumour cells using the Zika virus
Towards a new therapy against childhood brain cancer: How does the Zika virus kill aggressive brain tumour cells?
Evaluating the use of novel treatments in combination with current maintenance therapies for the on-going treatment of high-risk neuroblastomas
Evaluating the efficacy of Enhancer of Zeste Homolog 2 (EZH2) inhibitors in combination with anti-GD2/isotretinoin for the treatment of high-risk neuroblastoma: a pre-clinical study